Go to deals
Healthcare

GeneTech Inc. has been acquired by Eurofins

Noritsu Koki Co., Ltd. has sold GeneTech Inc. to Eurofins Clinical Testing Holding Lux S.à r.l.

GeneTech is a provider of non-invasive prenatal genetic tests (NIPT). The tests can only be taken at facilities certified by the Japanese Association of Medical Sciences. As a result of these efforts, GeneTech has carried out more than 90% of the NIPT tests conducted in Japan. Additionally, based on the achievements and experience accumulated, the firm has delivered various academic information and peripheral services to medical institutions.

Incorporated in 2014, Eurofins Clinical Testing Holding Lux S.à r.l. is a global clinical test service provider based in Luxembourg.

Founded in 1951, Noritsu Koki is a Tokyo Stock First Section listed public conglomerate specializing in manufacturing and healthcare businesses.

Oaklins’ team in Japan acted as the exclusive financial advisor to Noritsu Koki Co., Ltd. in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

 Taro  Okayama

Taro Okayama

Managing Director

Tokyo, Japan
Oaklins SXA
 Yasuhiro  Yasumuro

Yasuhiro Yasumuro

Director

Tokyo, Japan
Oaklins SXA

Related deals

Groupe Nature acquires Winco
Consumer & Retail | Healthcare

Groupe Nature acquires Winco

Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.

Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
Consumer & Retail | Healthcare

Camelia pharmacy chain has been acquired by Medigate Management UAB

CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.

Learn more
Shield Therapeutics has raised funds
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Learn more